{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T18:51:56Z","timestamp":1770663116471,"version":"3.49.0"},"reference-count":41,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T00:00:00Z","timestamp":1619654400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100004952","name":"Atlantic Canada Opportunities Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004952","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["alz-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Alzheimer's &amp;amp; Dementia"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>INTRODUCTION<\/jats:title><jats:p>The Clinician's Interview\u2010Based Impression of Change Plus caregiver input (CIBIC\u2010Plus) has been widely used in dementia drug trials to evaluate cognition, behavior, and function. New trials of symptomatic drugs forecast renewed interest in this measure.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>To test its clinical meaningfulness, we examined how CIBIC\u2010Plus performed in two cholinesterase inhibitor trials compared to goal attainment scaling Scale (GAS) scores, a patient\u2010reported outcome measure.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Net goal attainment was seen for all but one GAS domains in subjects who improved on the CIBIC\u2010Plus. Subjects who improved initially on CIBIC\u2010Plus scores were likely to remain improved across all other outcomes for each trial's duration, except for Disability Assessment for Dementia scores.<\/jats:p><\/jats:sec><jats:sec><jats:title>DISCUSSION<\/jats:title><jats:p>The initial response to treatment, as assessed by CIBIC\u2010Plus, remained stable for most outcome measures. Even small CIBIC\u2010Plus improvement changes are associated with clinically meaningful change as assessed by GAS. Other tests detect decline better than improvement.<\/jats:p><\/jats:sec>","DOI":"10.1002\/alz.12242","type":"journal-article","created":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T00:20:27Z","timestamp":1619742027000},"page":"856-865","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["The Clinician's Interview\u2010Based Impression of Change (Plus caregiver input) and goal attainment in two dementia drug trials: Clinical meaningfulness and the initial treatment response"],"prefix":"10.1002","volume":"17","author":[{"given":"Justin","family":"Stanley","sequence":"first","affiliation":[{"name":"DGI Clinical Inc.  Halifax Nova Scotia Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan E.","family":"Howlett","sequence":"additional","affiliation":[{"name":"DGI Clinical Inc.  Halifax Nova Scotia Canada"},{"name":"Division of Geriatric Medicine Dalhousie University  Halifax Nova Scotia Canada"},{"name":"Department of Pharmacology Dalhousie University  Halifax Nova Scotia Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taylor","family":"Dunn","sequence":"additional","affiliation":[{"name":"DGI Clinical Inc.  Halifax Nova Scotia Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6674-995X","authenticated-orcid":false,"given":"Kenneth","family":"Rockwood","sequence":"additional","affiliation":[{"name":"DGI Clinical Inc.  Halifax Nova Scotia Canada"},{"name":"Division of Geriatric Medicine Dalhousie University  Halifax Nova Scotia Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,4,29]]},"reference":[{"issue":"11","key":"e_1_2_7_2_1","article-title":"Cerebrolysin for vascular dementia","volume":"2019","author":"Cui S","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_3_1","first-page":"CD001190","article-title":"Donepezil for dementia due to Alzheimer's disease","volume":"6","author":"Birks JS","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_4_1","first-page":"CD001191","article-title":"Rivastigmine for Alzheimer's disease","volume":"4","author":"Birks JS","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_5_1","first-page":"CD004746","article-title":"Galantamine for vascular cognitive impairment","volume":"1","author":"Birks J","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002093-199700112-00004"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-019-0529-5"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.02.018"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.03.003"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.03.008"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/0004867417747402"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2019.05.002"},{"issue":"6","key":"e_1_2_7_13_1","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/psyg.12171","article-title":"Treating agitation and aggression in patients with Alzheimer's disease with escitalopram","volume":"16","author":"\u017dmuc VL","year":"2016","journal-title":"Psychogeriatrics"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2019.06.4946"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2016.3423"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30371-5"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.2196\/13360"},{"issue":"2","key":"e_1_2_7_18_1","doi-asserted-by":"crossref","first-page":"85","DOI":"10.14283\/jpad.2018.49","article-title":"Assessment of clinical meaningfulness of endpoints in the generation program by the Insights to Model Alzheimer's Progression in Real Life (iMAP) Study","volume":"6","author":"Graf A","year":"2019","journal-title":"J Prev Alzheimers Dis"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2017.02.005"},{"key":"e_1_2_7_20_1","first-page":"105","article-title":"Function and clinical meaningfulness of treatments for mild Alzheimer's disease","volume":"2","author":"Siemers E","year":"2016","journal-title":"Alzheimers Dement"},{"issue":"2","key":"e_1_2_7_21_1","doi-asserted-by":"crossref","first-page":"98","DOI":"10.14283\/jpad.2018.15","article-title":"Identifying better outcome measures to improve treatment of agitation in dementia: a report from the EU\/US\/CTAD Task Force","volume":"5","author":"Sano M","year":"2018","journal-title":"J Prev Alzheimers Dis"},{"issue":"2","key":"e_1_2_7_22_1","first-page":"67","article-title":"Getting more clinically meaningful measures of functional impairment for Alzheimer's Disease","volume":"4","author":"Fillit H","year":"2017","journal-title":"J Prev Alzheimers Dis"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l6217"},{"key":"e_1_2_7_24_1","article-title":"Benefits and harms of prescription drugs and supplements for treatment of clinical alzheimer\u2010type dementia: a systematic review and meta\u2010analysis","volume":"10","author":"Fink HA","year":"2020","journal-title":"Ann Intern Med"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1159\/000109923"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1497.1998.00203.x"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/153331759701200303"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01530764"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.73.5.500"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.051432"},{"issue":"5","key":"e_1_2_7_31_1","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1017\/S1041610208007230","article-title":"Decreased initiation of usual activities in people with mild\u2010to\u2010moderate Alzheimer's disease: a descriptive analysis from the VISTA clinical trial","volume":"20","author":"Cook C","year":"2008","journal-title":"Int Psychogeriatr"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/WAD.0b013e318193cbef"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1098\/rsif.2014.0378"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1159\/000054761"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1177\/0962280218777896"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-019-0866-x"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1177\/089198879600900404"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25380"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008671"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30371-5"},{"issue":"12","key":"e_1_2_7_41_1","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1111\/febs.15264","article-title":"Discovery, development, and future application of senolytics: theories and predictions","volume":"1287","author":"Wissler Gerdes EO","year":"2020","journal-title":"FEBS J"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(03)00533-7"}],"container-title":["Alzheimer's &amp; Dementia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/alz.12242","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/alz.12242","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/alz.12242","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:14:17Z","timestamp":1759882457000},"score":1,"resource":{"primary":{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/10.1002\/alz.12242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,29]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["10.1002\/alz.12242"],"URL":"https:\/\/doi.org\/10.1002\/alz.12242","archive":["Portico"],"relation":{},"ISSN":["1552-5260","1552-5279"],"issn-type":[{"value":"1552-5260","type":"print"},{"value":"1552-5279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,29]]},"assertion":[{"value":"2020-05-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}